Ad is loading...
ADNRX vs PAMCX
ADNRX vs PAMCX Comparison
Open Charts ADNRX vs PAMCX
American Beacon ARK Transfmt Innov R6
Price$12.89
Change-$0.15 (-1.15%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth Adv
Price$103.39
Change-$0.73 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
VS
VS
ADNRX vs PAMCX Comparison Chart
Loading...
ADNRX vs. PAMCX commentary
Sep 21, 2024
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADNRX is a Sell and PAMCX is a StrongBuy.
FUNDAMENTALS
Fundamentals
PAMCX has more cash in the bank: 31.4B vs. ADNRX (195M). ADNRX (0.00) and PAMCX (0.00) have matching dividends . ADNRX was incepted earlier than PAMCX: ADNRX (4 years) vs PAMCX (24 years). ADNRX is a more actively managed with annual turnover of: 33.00 vs. PAMCX (21.70). ADNRX has a lower initial minimum investment than PAMCX: ADNRX (0) vs PAMCX (2500). ADNRX annual gain was more profitable for investors over the last year : 11.89 vs. PAMCX (10.53).
| ADNRX | PAMCX | ADNRX / PAMCX | |
| Total Expense Ratio | N/A | N/A | - |
| Annual Report Gross Expense Ratio | N/A | N/A | - |
| Fund Existence | 4 years | 24 years | - |
| Gain YTD | -11.560 | 7.936 | -146% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 2500 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 195M | 31.4B | 1% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 11.89 | 10.53 | 113% |
| Returns for 3 years | -71.65 | -16.76 | 427% |
| Returns for 5 years | N/A | 11.14 | - |
| Returns for 10 years | N/A | 34.74 | - |
View a ticker or compare two or three
VS
VS
Ad is loading...